CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

Amgen's weight loss drug only needs to be taken once a month The top GLP-1 treatments on the market today require weekly injections. But MariTide, which is Amgen's GLP-1 drug, only needs to be ...

The medication can be taken monthly by injection and resulted in an average weight loss of up to 20% over 52 weeks, according to data released by the company. Unlike other treatments, MariTide has ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

MariTide Phase 3 studies to begin in first half ... placed a hold on an early-stage trial of a different experimental weight-loss drug. The company's shares, which have gained more than 11% ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...

Management strongly denied that its weight loss drugs had suffered "misssteps", but personally, I am beginning to wonder if MariTide is the "real deal". While Amgen stated in November that "there ...